Porton Biopharma Digital Brochure - page 6

Porton Biopharma’s strategy as a new company with a distinguished
heritage is to grow our existing business, develop our product pipeline
and build relationships across the industry. We were corporatised out
of Public Health England on 1st April 2015, to enable us to grow the
business of developing and manufacturing life-saving products.
The company is built upon decades of biopharmaceutical experience,
including the successful licensure of many therapies that now save
thousands of lives every year and generate revenues from world-
wide sales. We have state-of-the-art cGMP manufacturing facilities
which are licensed by the MHRA and FDA where we manufacture
our own biopharmaceutical products. With a multi-skilled workforce
of approximately 300 and an ongoing programme of investing in our
facilities, we are focused on continual improvement and the delivery
of products that make a real difference to patients’ lives.
At PBL we offer expertise in developmental production of biologicals,
including product characterisation, process and analytical validation,
and scalability for market. Allied with experience of regulatory
compliance gained from the licensure of our own products, this puts
us in an ideal position to offer expertise and enable our partners to
successfully bring their products to market.
Our mission is to protect patients’ health through
the quality-assured development and production
of biopharmaceuticals.
1,2,3,4,5 7,8
Powered by FlippingBook